ACTRIMS 2022 | Investigating subcutaneous immunoglobulin therapy in MOGAD

Whilst intravenous immunoglobulin (IVIg) is currently administered for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), subcutaneous formulations represent a possible alternative to IVIg. Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, discusses the efficacy of subcutaneous immunoglobulin therapy in treating MOGAD. In a retrospective study comparing the two routes of administration, subcutaneous immunoglobulin therapy was found to be as efficacious as IVIg with fewer side effects including aseptic meningitis and headaches. Despite the increased cost and discomfort around the site of infusion, subcutaneous immunoglobulin therapy is a viable alternative to IVIg for patients who cannot tolerate intravenous injections. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.